Provided by Tiger Trade Technology Pte. Ltd.

Abeona Therapeutics

5.98
+0.13002.22%
Post-market: 5.94-0.0400-0.67%19:30 EDT
Volume:683.83K
Turnover:4.06M
Market Cap:341.15M
PE:-5.34
High:6.00
Open:5.80
Low:5.79
Close:5.85
52wk High:7.65
52wk Low:4.00
Shares:57.05M
Float Shares:36.92M
Volume Ratio:0.77
T/O Rate:1.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1200
EPS(LYR):1.01
ROE:-43.13%
ROA:-24.55%
PB:2.66
PE(LYR):5.92

Loading ...

Abeona Therapeutics Tightens Shareholder Meeting and Governance Rules

TIPRANKS
·
Mar 21

Abeona Therapeutics adopts third amended and restated bylaws and raises stockholder meeting quorum to 50%

Reuters
·
Mar 21

Abeona Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 19

Abeona Therapeutics (ABEO) One Off US$152.4m Gain Tests Bullish Profitability Narrative

Simply Wall St.
·
Mar 19

Abeona Therapeutics 2025 net income slightly misses estimates on higher SG&A costs

Reuters
·
Mar 17

Abeona Therapeutics Q4 EPS $(0.34) Beats $(0.36) Estimate, Sales $5.420M Beat $5.270M Estimate

Benzinga Earnings
·
Mar 17

Abeona Therapeutics reports 2025 EPS $1.01 vs. ($1.55) last year

TIPRANKS
·
Mar 17

Abeona Therapeutics FY2025 SG&A expenses jumped 117.6% to USD 65.03 million

Reuters
·
Mar 17

Abeona Therapeutics FY Income From Operations USD -89.448 Million VS. Ibes Estimate USD -78.4 Million

THOMSON REUTERS
·
Mar 17

Corrected-Abeona Therapeutics FY Cash & Investments USD 191.4 Million (Corrects Amount)

THOMSON REUTERS
·
Mar 17

Press Release: Abeona Therapeutics(R) Reports Full Year 2025 Financial Results and Corporate Updates

Dow Jones
·
Mar 17

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 16

Abeona Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
Mar 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 13

Abeona Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 10

Abeona says ZEVASKYN launch gains momentum as commercial payer coverage reaches 80% of insured lives

Reuters
·
Mar 09

Abeona Therapeutics Inc: Additional Biopsies for Zevaskyn Are Scheduled for Remainder of This Quarter.

THOMSON REUTERS
·
Mar 09

Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch

GlobeNewswire
·
Mar 09